Patrick Vélicitat

493 total citations
13 papers, 320 citations indexed

About

Patrick Vélicitat is a scholar working on Pharmacology, Epidemiology and Rheumatology. According to data from OpenAlex, Patrick Vélicitat has authored 13 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 4 papers in Epidemiology and 3 papers in Rheumatology. Recurrent topics in Patrick Vélicitat's work include Drug-Induced Adverse Reactions (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Urinary Tract Infections Management (3 papers). Patrick Vélicitat is often cited by papers focused on Drug-Induced Adverse Reactions (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Urinary Tract Infections Management (3 papers). Patrick Vélicitat collaborates with scholars based in France, Germany and United States. Patrick Vélicitat's co-authors include Erich Bluhmki, J. M. Le Parc, R.-L. Dreiser, Paola Motta, Philipp Knechtle, Eric Veys, Andrei Călin, H. Zeidler, Maxime Dougados and Antoine Guéguen and has published in prestigious journals such as JAMA, Antimicrobial Agents and Chemotherapy and Clinical Pharmacokinetics.

In The Last Decade

Patrick Vélicitat

11 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Vélicitat France	10	167	82	63	40	40	13	320
Carmen Fucile Italy	12	152 0.9×	7 0.1×	68 1.1×	79 2.0×	12 0.3×	25	392
Fillastre Jp France	9	72 0.4×	17 0.2×	29 0.5×	31 0.8×	13 0.3×	81	316
Atanu Kumar Dutta India	10	55 0.3×	9 0.1×	29 0.5×	55 1.4×	10 0.3×	30	332
Heike Oberwittler Germany	8	82 0.5×	18 0.2×	10 0.2×	89 2.2×	22 0.6×	10	357
Holly Kelly United States	8	54 0.3×	14 0.2×	9 0.1×	28 0.7×	22 0.6×	12	456
Gonzalo Hijos Spain	8	46 0.3×	20 0.2×	5 0.1×	36 0.9×	19 0.5×	26	260
Elahe Mohammadi Iran	10	31 0.2×	7 0.1×	64 1.0×	49 1.2×	70 1.8×	19	345
Lee Cc Taiwan	11	73 0.4×	11 0.1×	20 0.3×	62 1.6×	16 0.4×	43	339
Gareth Brock United Kingdom	6	46 0.3×	14 0.2×	10 0.2×	8 0.2×	140 3.5×	13	530

Countries citing papers authored by Patrick Vélicitat

Since Specialization

Citations

This map shows the geographic impact of Patrick Vélicitat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Vélicitat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Vélicitat more than expected).

Fields of papers citing papers by Patrick Vélicitat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Vélicitat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Vélicitat. The network helps show where Patrick Vélicitat may publish in the future.

Co-authorship network of co-authors of Patrick Vélicitat

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Vélicitat. A scholar is included among the top collaborators of Patrick Vélicitat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Vélicitat. Patrick Vélicitat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Kaye, Keith S., et al.. (2022). Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis. JAMA. 328(13). 1304–1304. 61 indexed citations

Kaye, Keith S., et al.. (2021). 637. Treatment Outcomes in Secondary Analysis Populations of Adult Patients the ALLIUM Phase 3 study Comparing Cefepime-Enmetazobactam to Piperacillin-Tazobactam for Complicated Urinary Tract Infections (cUTI) or Acute Pyelonephritis (AP). Open Forum Infectious Diseases. 8(Supplement_1). S421–S421.

Das, Shampa, Richard J. Fitzgerald, Asad Ullah, et al.. (2020). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy. 65(1). 25 indexed citations

Belley, Adam, et al.. (2020). LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales. Open Forum Infectious Diseases. 7(Supplement_1). S845–S845. 2 indexed citations

Moreau, Jean‐Paul, et al.. (2004). 61 Enquête descriptive sur la bronchopneumopathie chronique obstructive (BPCO) en pneumologie libérale : définition des caractéristiques des patients et appréciation du retentissement fonctionnel et socio-professionnel. Revue des Maladies Respiratoires. 21. 34–34.

Combe, Bernard, et al.. (2001). Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflammation Research. 50(S1). 10–16. 16 indexed citations

Dreiser, R.-L., et al.. (2001). Oral meloxicam is effective in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac. Inflammation Research. 50(S1). 17–23. 44 indexed citations

Euller-Ziegler, L, Patrick Vélicitat, Erich Bluhmki, et al.. (2001). Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflammation Research. 50(S1). 5–9. 31 indexed citations

Vélicitat, Patrick, et al.. (2000). Improved delivery of ipratropium bromide using Respimat®(a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respiratory Medicine. 94(5). 490–495. 17 indexed citations

10.

Lapicque, F., P Vergne, Damien Lœuille, et al.. (2000). Articular Diffusion of Meloxicam After a Single Oral Dose. Clinical Pharmacokinetics. 39(5). 369–382. 16 indexed citations

11.

Dougados, Maxime, Antoine Guéguen, Patrick Vélicitat, et al.. (1999). Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis.. PubMed. 26(4). 971–4. 64 indexed citations

12.

Bernhardt, M. Brooke, et al.. (1996). Tolerability of Multiple Administration of Intramuscular Meloxicam: A Comparison with Intramuscular Piroxicam in Patients with Rheumatoid Arthritis or Osteoarthritis. Lara D. Veeken. 35(suppl 1). 51–55. 20 indexed citations

13.

Auvinet, B., et al.. (1995). Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica. Clinical Therapeutics. 17(6). 1078–1090. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact